Collaborative research

Research is done, by definition, through collaborations. At Imagine, one of the rare centers in the world to offer an integrated doctor-researcher-patient approach in a single place, there is a strong desire to collaborate and promote cross-disciplinarity to develop advances and knowledge on genetic diseases.

Research Acceleration

Search together to benefit the largest number of people

Since its founding, Imagine has boosted the development of cross-disciplinary projects within research laboratories and teams. To give momentum to its innovative projects, an internal funding program was created: cross-lab. Promoting cross-disciplinarity, it aims to produce a leverage effect to raise the major public, national or European funds needed.

In 2018 alone, 5 new cross-lab projects were created. They involve no less than 14 labs, 7 reference centers for rare diseases and 3 core facilities, and concern various fields: hemophagocytic lymphohistocytosis and the single cell, developmental and pathological cell death in fetal and postnatal microcephaly, application of artificial intelligence in dysmorphology, mitochondrial DNA maintenance defects and dysregulation of the immune response, and inborn errors of kerotinocyte-leukocyte interaction.

Partner with the best in France and internationally

Since 2019, one of these Cross-lab programs initiated in 2017 on autoimmune and inflammatory diseases has benefited from the status “University Hospital Research in health” of the French Investments for the Future program, aiming to support innovative and large-scale research projects in the field of health. The ATRACTion project, led by Prof. Frédéric Rieux-Laucat at imagine Institute, associates several laboratories at Imagine and 10 academic partners (AP-HP, Inra, CEA, Pasteur Institute, Curie Institute, University of Paris, Sorbonne University, Inserm) or industry partners. It is based on multiple studies of single-cell analysis in particular, and on analysis of this big data by artificial intelligence. It relies on a consortium of 10 partners - in addition to Imagine - academic (AP-HP, Inra, CEA, Pasteur Institute, Curie Institute, University of Paris, Sorbonne University, Inserm) or industry. This project therefore paves the way for a much more personalized medicine and new therapeutic solutions based on new molecules or repositioning molecules already used in other diseases.

In 2017, the C’IL-LICO “Medicine of the future for ciliopathies with renal failure” led by Imagine was also among the 10 winners of the RHU call for projects selected by ANR. It aims to develop new diagnostic and therapeutic tools for patients suffering from these pathologies. The project, led by Prof. Stanislas Lyonnet over 5 years, also relies on a collaboration between the teams led by Sophie Saunier, Antonio Rausell, Nicolas Garcelon and Anita Burgun at Imagine with experts from Inserm, AP-HP, Strasbourg University hospital, Ecole Polytechnique and industry partners Alexion then Medetia SAS.